Partner Headlines - BMRN

  1. BIOMARIN PHARMA

    IBD
  2. State Of The Union Lights Up Biotech

    Benzinga
  3. Nomura Analyst Sees Fast Growth At BioMarin Pharmaceutical

    Benzinga
  4. UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical ...

    Benzinga
  5. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  6. Regeneron Jumps On Favorable Cholesterol Drug Report

    IBD
  7. 5 Potential Blockbuster Drugs Set To Launch In 2015

    IBD
  8. What Investors Are Looking For In NPS Pharmaceuticals Ahead Of ...

    Benzinga
  9. BioMarin CEO Sees Big Future For Prosensa Drug

    IBD
  10. UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical ...

    Benzinga
  11. FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion ...

    Benzinga
  12. BioMarin Will Report Breadth of Innovative Development Pipeline ...

    Benzinga
  13. Benzinga's M&A Chatter for Monday November 24, 2014

    Benzinga
  14. BioMarin buying Prosensa

    IBD
  15. Trio Of Major Deals Disclosed

    IBD
  16. Mid-Afternoon Market Update: Trina Solar Drops After Quarterly ...

    Benzinga
  17. Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters ...

    Benzinga
  18. Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire ...

    Benzinga
  19. Benzinga's Volume Movers

    Benzinga
  20. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD
  21. Stocks Hitting 52-Week Highs

    Benzinga
  22. Morning Market Movers

    Benzinga
  23. Stock Futures Trending Higher; Kate Spade Bags An Upgrade

    IBD
  24. BioMarin Pharmaceuticals To Acquire Prosensa

    Benzinga
  25. Benzinga's Top #PreMarket Gainers

    Benzinga
  26. US Stock Futures Up Ahead Of Economic Data

    Benzinga
  27. Stocks Hitting 52-Week Highs

    Benzinga
  28. Benzinga's Top Upgrades

    Benzinga
  29. Benzinga's M&A Chatter for Tuesday October 21, 2014

    Benzinga
  30. BioMarin Weathers The Storm

    Benzinga
  31. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD
  32. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD
  33. UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical

    Benzinga
  34. Benzinga's Top Upgrades

    Benzinga
  35. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  36. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, ...

    Benzinga
  37. Top Trending Tickers On StockTwits For February 18

    Benzinga
  38. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga
  39. You Can No Longer Ignore Biotech

    GuruFocus
  40. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  41. Celgene, Dendreon Lead Short Interest Trend In Biotechs (BMRN, ...

    Benzinga
  42. UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical ...

    Benzinga
  43. UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On ...

    Benzinga
  44. BioMarin Wins FDA Panel Vote, Cuts Deal With Myriad

    IBD
  45. Benzinga's Top #PreMarket Gainers

    Benzinga
  46. BioMarin Confirms FDA Panel Recommends Approval of Vimizim for ...

    Benzinga
  47. BioMarin Stock Trading Halted Today for FDA Endocrinologic and ...

    Benzinga
  48. Gilead Sciences Leads In Rising Short Interest Among Biotechs ...

    Benzinga
  49. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts
  50. BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA ...

    Benzinga
  51. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics ...

    Benzinga
  52. US Oncology, Biomarin Announce Collaboration to Launch PARP Inhibitor ...

    Benzinga
  53. Roche

    IBD
  54. BioMarin Announces 5 Poster Presentations on BMN 673 at AACR-NCI-EORTC ...

    Benzinga
  55. Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

    Benzinga
  56. Orphan Drugs: No (Payer) News Is Good News

    YCharts
  57. BioMarin Presents Positive Phase 1/2 Data on BMN 673 in Breast ...

    Benzinga
  58. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, ...

    Benzinga
  59. Market Primer: Friday, September 20: US Markets Fall As Investors ...

    Benzinga
  60. Benzinga's M&A Chatter for Thursday September 19, 2013

    Benzinga
  61. Report: Roche Lines up $15B in Debt to Buy BioMarin

    FoxBusiness
  62. Benzinga's Volume Movers

    Benzinga
  63. Benzinga's Top Pre-Market Gainers

    Benzinga
  64. UPDATE: Stifel Downgrades BioMarin Pharmaceutical on Appropriate ...

    Benzinga
  65. Benzinga's Top Pre-Market Gainers

    Benzinga
  66. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    Benzinga
  67. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  68. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  69. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  70. UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts

    Benzinga
  71. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  72. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  73. J.P. Morgan Reiterates Overweight Rating, $60 PT on BioMarin ...

    Benzinga
  74. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  75. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  76. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  77. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  78. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  79. UPDATE: Wedbush Reiterates BioMarin Pharmaceuticals at Neutral ...

    Benzinga
  80. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  81. BioMarin, Prestige Brands and Other Top Performing Health Care ...

    Benzinga
  82. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  83. Weekly Top Insider Sells? AAPL, GILD, BMRN, and PCLN

    GuruFocus
  84. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  85. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  86. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  87. Myriad Genetics Stock Hits High On Earnings Beat

    IBD
  88. Highs & Lows: BioMarin Pharmaceutical, Best Buy, and Skullcandy

    SchaeffersResearch
  89. BioMarin soars on drug data

    IBD
  90. Mid-Afternoon Market Update: Markets Rally, Vringo Jumps

    Benzinga
  91. UPDATE: Canaccord Genuity Raises PT to $56 on BioMarin Pharmaceutical ...

    Benzinga
  92. Mid Morning Market Update: Markets Decline, Stifel Financial ...

    Benzinga
  93. Stocks Hitting 52-Week Highs

    Benzinga
  94. BioMarin Stock Soars On Positive Drug Data

    IBD
  95. BioMarin Phase 3 Study of GALNS Meets Primary Endpoint

    Benzinga
  96. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  97. BioMarin Pharmaceutical Inc. Reports Operating Results (10-Q)

    GuruFocus
  98. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  99. UPDATE: Jefferies Raises PT to $46 on BioMarin Pharmaceutical ...

    Benzinga
  100. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
Trading Center